BMJ:加巴喷丁、普瑞巴林与神经精神系统障碍

2019-06-18 MedSci MedSci原创

研究认为,服用加巴喷丁类药物与自杀行为、服药过量、头部/身体伤害、道路交通事故和犯罪的风险增加有关。与加巴喷丁相比,普瑞巴林的危险性更高

近日研究人员考察了加巴喷汀类药物与协调障碍(头部、身体伤害或道路交通事故)、精神健康(自杀行为、非故意用药过量)和犯罪等不良事件的关系。

本次研究为基于人群的队列研究,在瑞典进行,191973名患者在2006-2013年使用了普瑞巴林或加巴喷丁,主要结果是自杀行为、非故意过量服药、头部/身体伤害、道路交通事故和犯罪,以及因暴力犯罪被捕。

在研究期间,10026(5.2%)名参与者因自杀行为接受治疗或死于自杀,17144(8.9%)名参与者出现过量服药,12070(6.3%)名参与者出现道路交通事故或犯罪,70522(36.7%)名参与者出现头部或身体受伤,7984(4.1%)名参与者因暴力犯罪被捕。在个体分析中,加巴喷丁治疗导致自杀行为和自杀死亡(年龄调整后的危险比为1.26)、药物过量(1.24)、头部/身体伤害(1.22)和道路交通事故和犯罪(1.13)风险增加。单独检查药物时,普瑞巴林与所有结果的危险性增加相关,而加巴喷丁的相关性不显著。当按年龄分层时,15-24岁人群风险增加最为显著。

研究认为,服用巴喷丁类药物与自杀行为、服药过量、头部/身体伤害、道路交通事故和犯罪的风险增加有关。与加巴喷丁相比,普瑞巴林的危险性更高。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1848765, encodeId=a4c81848e65d7, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 10 12:59:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369077, encodeId=6d1c3690e779, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Fri Jul 05 06:58:08 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368394, encodeId=a53236839414, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Wed Jun 26 17:35:15 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368154, encodeId=ebf436815489, content=好好学习,天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05155126416, createdName=146480bem82暂无昵称, createdTime=Sat Jun 22 10:21:49 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310307, encodeId=94bf131030e36, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Jun 20 10:59:00 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
    2020-03-10 柳叶一刀
  2. [GetPortalCommentsPageByObjectIdResponse(id=1848765, encodeId=a4c81848e65d7, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 10 12:59:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369077, encodeId=6d1c3690e779, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Fri Jul 05 06:58:08 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368394, encodeId=a53236839414, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Wed Jun 26 17:35:15 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368154, encodeId=ebf436815489, content=好好学习,天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05155126416, createdName=146480bem82暂无昵称, createdTime=Sat Jun 22 10:21:49 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310307, encodeId=94bf131030e36, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Jun 20 10:59:00 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
    2019-07-05 百草

    666

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1848765, encodeId=a4c81848e65d7, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 10 12:59:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369077, encodeId=6d1c3690e779, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Fri Jul 05 06:58:08 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368394, encodeId=a53236839414, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Wed Jun 26 17:35:15 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368154, encodeId=ebf436815489, content=好好学习,天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05155126416, createdName=146480bem82暂无昵称, createdTime=Sat Jun 22 10:21:49 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310307, encodeId=94bf131030e36, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Jun 20 10:59:00 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
    2019-06-26 百草

    666

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1848765, encodeId=a4c81848e65d7, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 10 12:59:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369077, encodeId=6d1c3690e779, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Fri Jul 05 06:58:08 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368394, encodeId=a53236839414, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Wed Jun 26 17:35:15 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368154, encodeId=ebf436815489, content=好好学习,天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05155126416, createdName=146480bem82暂无昵称, createdTime=Sat Jun 22 10:21:49 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310307, encodeId=94bf131030e36, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Jun 20 10:59:00 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
    2019-06-22 146480bem82暂无昵称

    好好学习,天天向上

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1848765, encodeId=a4c81848e65d7, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 10 12:59:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369077, encodeId=6d1c3690e779, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Fri Jul 05 06:58:08 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368394, encodeId=a53236839414, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Wed Jun 26 17:35:15 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368154, encodeId=ebf436815489, content=好好学习,天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05155126416, createdName=146480bem82暂无昵称, createdTime=Sat Jun 22 10:21:49 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310307, encodeId=94bf131030e36, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Jun 20 10:59:00 CST 2019, time=2019-06-20, status=1, ipAttribution=)]

相关资讯

BMC Anesthesiol:加巴喷丁和雷莫司琼联合应用可更好地预防妇科腹腔镜手术后PONV的发生

加巴喷丁最初是作为一种抗惊厥的药物,最近证明表明加巴喷丁还可用于恶心和呕吐的治疗。本研究旨在在妇科腹腔镜手术后接受芬太尼自控镇痛的患者中对比口服加巴喷丁与雷莫司琼联合加巴喷丁的止吐效果。 研究共纳入了130名全麻下接受妇科腹腔镜手术的患者,将其随机分为三组:G组麻醉前1 h接受300毫克口服加巴喷丁,R组在手术结束时给予0.3 mg雷莫司琼,GR组麻醉前1 h接受300毫克口服加巴喷丁,术后

PLoS Med:加巴喷丁是否增加阿片类药物相关死亡风险?

2017年10月,发表在《PLoS Med》上的一项基于人群的巢式病例对照研究,调查了加巴喷丁和阿片类药物联用与阿片类药物相关死亡风险增加的相关性。研究结果表明:同时使用加巴喷丁与阿片类药物相关死亡风险的大幅增加相关,因此医师应慎重开具处方。其他相关药物的使用风险也应被进一步探究。

JAMA Surg:围手术期加巴喷丁可减少阿片类止痛药的使用率

研究认为,围手术期加巴喷丁不能缓解术后疼痛,但可以减少术后阿片类药物使用率,降低慢性阿片药物使用风险

Drug Safety:加巴喷丁过量会增加患者住院或使用急诊服务的几率?

2017年发表在《Drug Saf》上的一项回顾性队列分析,评估了与过量使用加巴喷丁和/或阿片类药物相关的全因和药物相关医疗事件。

Anesthesiology:加巴喷丁不会减少老年手术患者术后谵妄:一项随机临床试验

术后疼痛和阿片类药物使用与术后谵妄有关。我们设计了一项单中心,随机,安慰剂对照,平行臂,双盲试验,以确定围手术期加巴喷丁使用是否减少非心脏手术术后谵妄。

J Neurosurg Anesth:加巴喷丁术前给药可改善行开颅术患者术后急性镇痛效果:随机对照实验

术前使用加巴喷丁可明显减轻经枕下或颞下开颅手术患者急性术后疼痛,同时减少呕吐的发生率。然而,当使用加巴喷丁进行多模式镇痛时应注意术后早期镇静。